A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Tildrakizumab (Primary) ; Etanercept
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Sun Pharma Global FZE; Sun Pharmaceutical Industries
Most Recent Events
- 26 Feb 2025 Planned End Date changed from 23 Jul 2031 to 5 Dec 2031.
- 26 Feb 2025 Planned primary completion date changed from 23 May 2031 to 13 Jul 2025.
- 26 Feb 2025 Status changed from active, no longer recruiting to recruiting.